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Abstract
Background
Respiratory viral infections follow an unpredictable clinical course in young children ranging
from a common cold to respiratory failure. The transition from mild to severe disease occurs
rapidly and is difficult to predict. The pathophysiology underlying disease severity has
remained elusive. There is an urgent need to better understand the immune response in
this disease to come up with biomarkers that may aid clinical decision making.
Methods
In a prospective study, flow cytometric and genome-wide gene expression analyses were
performed on blood samples of 26 children with a diagnosis of severe, moderate or mild
Respiratory Syncytial Virus (RSV) infection. Differentially expressed genes were validated
using Q-PCR in a second cohort of 80 children during three consecutive winter seasons.
FACS analyses were also performed in the second cohort and on recovery samples of
severe cases in the first cohort.
Results
Severe RSV infection was associated with a transient but marked decrease in CD4+ T,
CD8+ T, and NK cells in peripheral blood. Gene expression analyses in both cohorts identi-
fied Olfactomedin4 (OLFM4) as a fully discriminative marker between children with mild and
severe RSV infection, giving a PAM cross-validation error of 0%. Patients with an OLFM4
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gene expression level above -7.5 were 6 times more likely to develop severe disease, after
correction for age at hospitalization and gestational age.
Conclusion
By combining genome-wide expression profiling of blood cell subsets with clinically well-
annotated samples, OLFM4 was identified as a biomarker for severity of pediatric RSV
infection.
Introduction
Respiratory viral infections are an important cause of hospitalization among children younger
than 5 years of age. Human Respiratory Syncytial Virus (RSV) is the most common (40–85%)
identified virus in infants hospitalized for respiratory infections during winter epidemics, with
hospitalization rates between 1 and 2% [1–6]. Clinical manifestations range from common
colds to severe lower respiratory tract infections requiring mechanical ventilation. Risk factors
for a severe course are known, but the majority of patients admitted to an Intensive Care Unit
were previously healthy [7–9]. Since transition from mild to severe disease can occur within
hours, one of the key challenges for clinicians is to differentiate children who need hospitaliza-
tion for supportive care from those who can safely be discharged. Currently, young infants
with mild bronchiolitis, especially those younger than 12 weeks of age, are often admitted to a
hospital since they have an increased risk of severe disease. However, up to 35% of children
hospitalized with bronchiolitis do not receive any supportive intervention [10]. Conversely, it
is crucial to avoid early discharge of those children who may experience clinical deterioration.
Among children sent home with the diagnosis bronchiolitis, 4.6–6.8% require hospitalization
later on [11, 12].
Much research has been done on the immune response against RSV in humans. Several
reports suggested an important role for the innate immune system, while others found an inad-
equate adaptive immune response especially in young children and in individuals who present
with a severe clinical picture [13]. The uncertainty in the nature of the immune response
against RSV is reflected in the unpredictable clinical course of the infection as well as in the dif-
ficulty of developing an adequate vaccine. We as well as others previously reported that T lym-
phocytes can be markedly decreased in the more severe cases of the disease. We reported that
in severe cases both CD4 and CD8 T cell numbers, as well as NK cells were reduced in periph-
eral blood [14]. However, it remains unclear whether this indicates an inadequate immune
response against RSV, for instance by massive apoptosis or decreased production of T cells, or
that peripheral blood poorly reflects an ongoing immune response that might be very active.
The detection and application of biomarkers to assess severity of viral lower respiratory
tract infections, in particular RSV infection, may assist clinicians in the prediction of severe dis-
ease in children with bronchiolitis and may help to reduce the number of unnecessary hospital-
izations or clinical deterioration after discharge. Furthermore, markers for disease severity are
important research tools to study effects of interventions by new therapies or to stratify patients
by disease severity [15, 16]. Several studies have shown that transcriptional analysis of periph-
eral blood cells may be used to define different etiologies of disease and disease outcomes [17–
20]. In a seminal proof-of-concept study, Ramilo et al. (2007) compared the transcriptional
profiles of PBMCs of children with infectious diseases and identified a set of genes that can sep-
arate influenza A infections from bacterial infections (Staphylococcus aureus, Escherichia coli
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and Streptococcus pneumoniae) [20]. Recently this group also reported that these transcriptome
profiles also contained information regarding viral etiology (influenza, rhino virus and RSV)
and the course of disease [21].
This study was initiated to obtain insight into the changes occurring in adaptive and innate
immune cells during RSV infection and to identify possible biomarkers of disease severity. To
identify transcriptional biomarkers to separate mild from severe disease, genome-wide gene
expression analyses were performed on blood samples of 26 children with a diagnosis of severe,
moderate or mild RSV infection in two winter seasons. A validation cohort of 80 children span-
ning three other consecutive winter seasons by flow cytometry and Q-PCR was used to validate
various candidate biomarkers.
Material and Methods
Study design
In this prospective cohort study, 3 ml of Sodiumheperanized blood and nasopharyngeal sam-
ples were obtained from two cohorts of patients with RSV bronchiolitis within 24 hours after
first contact with the hospital. Medical history, demographic data, and clinical assessments
were collected from questionnaires and medical records. Exclusion criteria were corticosteroid
use in past 48 hours, congenital significant heart or lung disease and immunodeficiency, Pres-
ence of 15 different viral pathogens was tested by multiplex RT-PCR on nasopharyngeal sam-
ples as previously described [22]. Patients were classified retrospectively into three groups
based on severity of disease. The mild group included children without hypoxia or severe feed-
ing problems. The moderate group included children requiring hospitalization for supplemen-
tal oxygen (oxygen saturations<93%) and/or nasogastric feeding. Children requiring
mechanical ventilation were included in the severe group. Recovery samples were obtained 4–6
weeks after acute infection from children with moderate and severe disease. The first cohort
consisted of 26 patients with RSV infections, divided into mild (n = 9), moderate (n = 9) and
severe (n = 8) disease. From all moderate and severe diseased patients recovery samples were
obtained. This cohort was used for micro-array analysis and initial qPCR validation of genes of
interest. The second cohort comprised 80 children with viral lower respiratory tract infections
both RSV positive and negative, and was also divided into three groups: mild (n = 14), moder-
ate (n = 42) and severe (n = 24). This cohort was meant for validation purposes. All subjects
were recruited at two hospitals in Nijmegen, the Canisius Wilhelmina Hospital and the Rad-
boud university medical center, the Netherlands. The study protocols were approved by the
institutional review board (Commissie Mensgebonden Onderzoek: Regional Committee on
Research involving Human Subjects Arnhem-Nijmegen, The Netherlands) and were con-
ducted in accordance with the principles of the Declaration of Helsinki. Written informed con-
sent was obtained from the parents of all children.
RNA isolation and microarray gene expression analyses
Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation
(Lymphoprep, Axis Shield, Norway), counted and subsequently stored in Trizol reagent (Invi-
trogen, The Netherlands) at -80°C in the same laboratory by the same team for both cohorts.
RNA from PBMC was extracted using Trizol (Invitrogen Life Technologies) according to the
manufacturer’s protocol. Total RNA was isolated using the RNeasy Minikit (Qiagen). RNA
integrity and quality was assessed using capillary electrophoresis [RNA 6000 Nano LabChip
(Agilent)] on an Agilent Bioanalyzer 2100 system. RNA processing, target labeling and hybrid-
ization to gene expression arrays was performed by standard methods as described [23]. Biotin
labeled cRNA was obtained using the One-Cycle Eukaryotic Target Labeling Assay
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(Affymetrix), after which 15 μg of fragmented, biotin labeled cRNA was hybridized to Affyme-
trix GeneChip Human Genome U133 plus 2.0 arrays according to standard Affymetrix proto-
col (Affymetrix Inc, Santa Clara, CA).
Flow Cytometry
Immunophenotyping of cryopreserved PBMCs were performed after thawing. The following
combinations of markers and fluorescent antibodies were used: CD14–FITC, CD16.56–phyco-
erythrin, CD3–peridinin chlorophyll protein, CD19–allophycocyanin, CD4–phycoerythrin–
Cy7, and CD8–allophycocyanin–Cy7 (all Beckman Coulter, Miami, FL). Samples were
acquired immediately after staining on a BD FACSCanto (Becton Dickinson, Heidelberg, Ger-
many) and analyzed using flow cytometry analysis software (FlowJo analyses 7.6, Three Star,
Ashland, OR). The following subsets were defined: CD4+ T cells (CD4+CD3+CD8-), CD8 T
cells (CD8+CD4-CD3+), NK cells (CD3-CD56+), B cells (CD45+CD19+) and monocytes
(CD14+).
Data analysis
Quality control analyses were performed as previously described [23, 24]. Scanned images
were inspected for artifacts, percentage of calls present (<25%) and controls of RNA degrada-
tion. This led to some arrays being discarded. On each remaining array, probes labelled
outliers by the Affymetrix scanning software and overexposed probes (with maximum PM
intensity level>63.000) were removed. Subsequently, probesets with less than 8 probes
remaining were discarded. For each comparison, robust multichip analysis (RMA) was used
for background removal, quantile normalization of probe intensity levels and probe set sum-
marization. The resulting values were log2-transformed for further analysis, giving probeset
expression levels between 0 and 16. We then selected only those probesets that showed at least
a two-fold difference (up or down) on a minimum of two arrays with respect to the median
expression over all arrays in that particular comparison [24, 25]. Finally, Significance Analysis
of Microarrays (SAM, [26]) was applied to find differentially expressed probesets with a signifi-
cance level of q<0.05. To select only biologically relevant changes, we demanded additionally
that the absolute expression level was larger than log2(200) and that the absolute difference
between groups was larger than 2 fold.
In a subsequent supervised analysis, we trained a PAM classifier (“Prediction Analysis of
Microarrays” [27]), attempting to find a minimum number of discriminative genes that
yielded an optimal cross-validation error (i.e. the predicted test error). For visualization
purposes, samples were clustered based on selected probesets by complete linkage hierarchi-
cal clustering with 1-correlation as a distance measure, using the Matlab Bioinformatics
toolbox (Mathworks, Natick, MA). The original and processed data were deposited in the
NCBI Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo; GSE69606). All
microarray experiments were performed according to the MIAME guidelines.
RT-PCR
Real-time quantitative PCR was used to measure the expression of genes of interest. Initial vali-
dation of gene expression of OLFM4 detected in the first cohort was performed with SYBR
Green PCRMastermix (Applied Biosystems; P/N 4367659) with forward 5`- atcaaaa-
cacccctgtcgtc- 3`and reverse 5`- gctgatgttcaccacaccac-3`primers for OLFM4. Actin was used as
a reference gene with forward primer 5`- cgtcacacttcatgatggagttg-3`and reverse primer 5`-
cttccttcctgggcatgga-3`. After validation of the microarray, the second cohort was analyzed with
commercially available Taqman primers (OLFM4 Hs00360669_m1 and GAPDH
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Hs99999905_m1). All samples were run for 40 cycles in duplicate on an Applied Biosystems
7500 Fast Real-Time PCR System. Ct values of OLFM4 were normalized against the reference
gene GAPDH.
OLFM4 plasma measurement
OLFM4 concentrations were measured in randomly selected plasma samples of 49 patients
from the validation cohort by a commercial ELISA kit (E90162Hu, Uscn Live Science Inc.,
China) according to the instructions of the manufacturer.
Published microarray data mining
A data mining search was performed in NCBI GEO and in EBI Arrayexpress, online databases
with datasets and profiles of previously performed microarray studies to validate our results
[28, 29]. Terms for searching were: OLFM4, Affymetrix, whole blood children, RSV and/or
homo sapiens. More than 90 microarray studies were found. Based on the population (chil-
dren/infants), sample size, disease type and available information per sample, 18 studies were
selected. From the series matrix files, the results were log transformed and OLFM4 gene
expression was selected and analyzed to gain insight in its behavior in different disease states
and ages.
Statistics
The distributions of categorical variables are presented as percentages per category. Numerical
variables are reported as means with standard deviation (SD) or medians with interquartile
ranges (IQR) depending on whether or not the variables were normally distributed (Kolmogo-
rov-Smirnov’s test, p>0.05). To determine whether OLMF4 was independently associated with
receiving mechanical ventilation, multivariable log-binomial regression analyses were per-
formed in the validation cohort resulting in adjusted Relative Risks (RR) [30]. Analysis were
performed with SPSS v21 and graphpad v5.
Results
We previously reported that RSV infection, especially in severe cases, was associated with lym-
phopenia. This was not only visible in NK and CD8+ T cells, known to be directly involved in
anti-viral immunity, but surprisingly also in CD4+ T cells, whereas B cells were unaffected
[14]. In the current study, we analyzed recovery samples of 6 severe patients after clearance of
the infection (on average 4 weeks after discharge) and found that the numbers of NK cells as
well as CD4+ and CD8+ T cells had returned to normal, indicating that the lymphopenia was
transient (S1 Fig).
Microarray analyses point to OLFM4 as a marker gene to classify
disease severity
Patients used for microarray analysis with a clinical diagnosis of mild disease were older at
time of admission to hospital than those with severe disease. The length of stay in hospital
increased with increasing disease severity. No statistically significant differences were seen in
gender, number of premature infants and duration of symptoms (Table 1). The microarray
analysis of PBMC of children with mild versus severe disease showed that 564 probesets were
expressed differentially (428 upregulated and 136 downregulated genes) under conditions as
described in material and methods (q<0.05;>2 fold difference; absolute expression
value> log2(200). As biomarkers should discriminate between non-disease and disease, the
Olfactomedin 4 Is Marker Severe Pediatric RSV Infections
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genes expressed differentially in children with mild versus severe disease as well as during
acute severe RSV infection versus recovery were selected. The analysis of paired acute and
recovery samples of children with severe RSV infection resulted in 808 differentially expressed
probesets (647 upregulated and 161 downregulated). Of these 808 probesets, 448 showed over-
lap with the 564 probesets in the comparison of mild versus severe disease, 365 genes being
upregulated and 83 genes being downregulated (Fig 1 and S2 Fig). Table 2 shows the top 25 of
up- and downregulated genes, of which Olfactomedin 4 (OLFM4) was the most upregulated
gene with a factor of over 40 fold. Since children in the severe group were younger compared to
those with mild disease, a paired age-matched subanalysis was performed among 7 severe
patients versus 7 patients with mild or moderate disease. This analysis resulted in 287 differen-
tially expressed probesets, all upregulated. The gene list of upregulated probesets did not differ
substantially from the main analysis. A supervised analysis (PAM) also identified OLFM4 as a
fully discriminative marker between children with mild and severe RSV infection, giving a
cross-validation error of 0%. As both SAM and PAM analyses revealed OLFM4 as a potentially
important marker for disease severity in children with RSV infection and OLFM4 has-to the
best of our knowledge- not been associated with respiratory tract infections before, this gene
Table 1. Patient characteristics. Values are given in numbers (percentages) and median with inter quartile range (IQR). P-values are based on Kruskall
Wallis tests, followed by MannWhitney U tests for individual comparisons:
Mild (N = 9) Moderate (N = 9) Severe (N = 8) p-value
Age (months) 8.7 [3.6–9.3] 1.9 [1.5–8.3] 2.4 [1.1–4.9] NS
Gender (male) 6 (67%) 8 (89%) 6 (75%) NS
Gestational age (wks) 40 [36.9–41.0] 38.6 [37.2–40.0] 35.1 [33.1–39.8] NS
Length of stay (days) 0 [0–3] 5 [2–9] 13 [6.3–19.8] p<0.001*
*mild vs moderate p<0.01, moderate vs severe p<0.05, mild vs severe p<0.001
doi:10.1371/journal.pone.0131927.t001
Fig 1. Venn diagramwith differentially expressed genes between groups. Differentially expressed
genes (q <0.05; >2 fold difference; absolute expression value >200) in patients with RSV infections
comparing patients with mild vs severe disease and during acute infection vs recovery in patients with
moderate and severe disease.
doi:10.1371/journal.pone.0131927.g001
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was chosen for further analysis. Interestingly, there was no marked upregulation of apoptosis
genes in the severe group, indicating that the observed lymphopenia was not caused by
increased apoptosis.
Validation of microarray findings by qPCR
To confirm our findings in the microarray analyses, qPCR was performed for OLFM4 in
PBMCs of the same patients. One patient in the moderate group was excluded since insuffi-
cient material was left. OLFM4 expression was statistically significantly higher in patients with
severe disease compared to those with mild and moderate disease (Fig 2A).
OLFM4 gene expression in PBMCs is increased during acute viral
respiratory infection and correlates with disease severity in a validation
cohort
The validation cohort consisted of 80 children with viral lower respiratory tract infections,
among which 47 had a confirmed RSV infection. This cohort reflects the patients presenting in
a paediatric ward during respiratory season prior to viral diagnostics, therefore both RSV posi-
tive and negative patients were analysed. The characteristics of these patients differed from
those of the patients in the discovery cohort, especially for age, gender, preterm birth, duration
Table 2. Top 25 up- and downregulated genes differentially expressed in PBMCs during severe RSV infection. Genes that showed overlap in both
the comparisons mild vs severe disease and severe vs recovery samples are shown.
Upregulated
genes
Fold difference mild vs
severe
Fold change severe vs
recovery
Downregulated
genes
Fold difference mild vs
severe
Fold change severe vs
recovery
OLFM4 49.7 43.2 GNLY -4.8 -4.0
MMP8 24.2 37.2 GZMH -4.5 -3.2
MMP8 24.1 33.6 GNLY -4.5 -3.7
CAECAM8 18.4 19.3 FGFBR2 -4.5 -5.1
ARG1 16.9 24.2 TRAC -3.9 -2.9
ANXA3 16.6 16.2 KLRF1 -3.8 -3.3
DEFA4 15.1 16.1 LGALS2 -3.7 -2.0
CA1 14.9 17.5 KLRC1 -3.7 -3.2
CHI3L1 13.9 11.0 KLRD1 -3.7 -3.0
LTF 13.0 12.6 TRAC -3.4 -2.8
SELENBP1 12.8 15.8 THOC4 -3.4 -3.1
CRISP3 12.3 12.3 GZMB -3.4 -2.3
ELANE 11.2 10.6 KLRD1 -3.4 -2.7
HP 11.0 11.9 IGHM -3.3 -2.0
CEACAM6 11.0 10.1 GZMK -3.3 -2.4
HBM 10.5 26.0 PRF1 -3.2 -2.2
CHI3L1 10.3 9.2 TRAC -3.1 -2.3
MPO 10.2 9.9 ITPKB -3.0 -3.5
ALAS2 10.2 21.7 SH2D1B -3.0 -2.6
IL1R2 10.2 10.5 SPON2 -3.0 -2.8
EPB42 10.1 15.3 PRF1 -3.0 -2.4
CEACAM6 10.1 9.7 TGFBR3 -2.9 -2.4
LCN2 10.1 10.3 FCER1A -2.9 -3.9
MPO 9.8 9.9 KLRB1 -2.9 -3.9
MMP9 9.8 11.6 GPR56 -2.9 -2.9
doi:10.1371/journal.pone.0131927.t002
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of symptoms. (S1 Table). In total, 115 PBMC samples were available for qPCR analysis, subdi-
vided in 80 acute and 35 recovery samples. OLFM4 gene expression levels during acute infec-
tion were higher compared to those obtained after recovery (p<0.001). In agreement with our
microarray analyses, expression of OLFM4 in PBMCs was higher in patients with severe dis-
ease compared to those with mild and moderate disease (Fig 2B). For the confirmed RSV posi-
tive patients only, OLFM4 expression also served as a discriminating marker, similar to the full
validation cohort (S3 Fig). Length of stay (LOS) in hospital, another measure for severity, was
also correlated positively with gene expression levels of OLFM4 (ρ = 0.402, p<0.001).
OLFM4 expression correlates with disease severity in PBMCs but not in
plasma
Since biomarkers in plasma are more easily obtained and processing is less time-consuming,
we measured protein levels of OLFM4 in plasma of 49 randomly selected patients of the valida-
tion cohort. Although OLFM4 plasma concentrations during acute infection were statistically
significantly higher compared to those in recovery samples, no association with disease severity
was observed (Fig 3). No correlation between protein levels and relative gene expression was
found either (ρ = 0.270, p = 0.088).
In a multivariable model OLFM4 gene expression is a statistically
significant marker for severe disease
To determine the predictive value of OLFM4 in patient with acute viral bronchiolitis, both
RSV positive and negative patients we performed a multivariable analysis. Relative OLMF4
gene expression, gender, gestational age, and age at time of hospital admission (in weeks) were
included as determinant and potential confounders, respectively in a multivariable model for
mechanical ventilation (Table 3).
For OLMF4, a cut-off value of> -7.5 was chosen, which corresponds with an OLFM4
expression level greater than 0.5% that of GAPDH. The unadjusted RR of mechanical
Fig 2. OLFM4 gene expression values of patients from themicro-array and validation cohort.OLFM4 gene expression levels were significantly higher
in patients with severe disease compared to those with mild and moderate disease in the micro-array cohort (Panel A) and an independent validation cohort
(Panel B). Expression levels are presented as ΔCt and median with inter quartile range (IQR). Statistics were performed by Kruskall Wallis tests, followed by
MannWhitney U tests for individual comparisons.
doi:10.1371/journal.pone.0131927.g002
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ventilation was 8.6 with a 95% confidence interval (CI) of 2.2–34.0. After adjustment for age
and gestational age, the RR was 6.1 (95%CI: 1.5–24.4), which indicates that children with
OLMF4 gene expression levels above -7.5 have a 6-fold increased risk of severe infection
requiring mechanical ventilation (Table 4). Gender did not add substantially to the final
model. Including OLMF4 gene expression in the model as a continuous variable resulted in an
age and gestational age adjusted RR of 1.20 (95%CI: 1.04–1.38), meaning that the risk of receiv-
ing mechanical ventilation increased by 20% with every step increase in expression level (range
-12.6 through -1.33).
Discussion
In this study we demonstrated that OLFM4 gene expression in PBMC is a previously unidenti-
fied classifier for severe disease in children with viral lower respiratory infections. OLFM4
expression was significantly increased during acute viral respiratory infections compared to
recovery samples. Moreover, an association was found between OLFM4 gene expression in
Fig 3. Plasma levels of OLFM4 in patients with viral RTI.OLFM4 plasma levels are statistically significantly higher during acute (n = 41) infections
compared to recovery samples (n = 25) (Panel A). However, there are no statistically significant differences among the three severity groups (Panel B).
Plasma levels (ng/ml) are presented as median with inter quartile range (IQR). Statistics were performed by MannWhitney U tests for comparison acute vs
recovery (p<0.05), and Kruskall Wallis tests for comparison mild vs moderate vs severe (p = 0.29).
doi:10.1371/journal.pone.0131927.g003
Table 3. Multivariable analysis of the association between OLFM4 expression levels and the risk of gettingmechanical ventilation. Values are
given in numbers (percentages) and mean ± standard deviation. MV = mechanical ventilation, NS = not significant, OR = odds ratio, CI = confidence interval
Characteristics Univariate analysis N = 80 Multivariate analysis
MV (n = 24) No MV (n = 56) p-value p-value p-value OR (95% CI)
Gender (male) 12 (50%) 30 (54%) NS NS - - -
Age (weeks) 1.22 [0.63–2.84] 3.95 [1.95–12.7] <0.001 <0.01; OR 0.96 0.05 0.96 0.93–1.00
OLFM4 expression -4.89 ± 2.53 -7.68 ±2.86 <0.001 4,71*10E-4; OR 1.43 <0.01 1.48 1.14–1.91
Premature (<37wks) 4 (17%) 11 (20%) NS NS - - -
Duration symptoms 11.0 [10.0–13.0] 5.0 [2.0–4.0] NS NS - - -
doi:10.1371/journal.pone.0131927.t003
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PBMCs and disease severity; in a multivariable model OLFM4 showed its power as a significant
marker for severe disease. Children with mechanical ventilation have almost 10 times more
often an increased OLFM4 expression in PBMC (greater than 0.05% of the GAPDh levels).
Therefore, OLFM4 fulfills the criteria as a biomarker for disease severity, in particular to dis-
criminate mild from severe cases in young infants. For OLFM4 to formally be used as prognos-
tic marker, a more extensive, prospective study will be required.
To the best of our knowledge, the OLFM4 gene has not been described in the context of
viral respiratory infections. Although changes in cell populations occur during the acute phase
of infection could be reflected in the gene expression profiles, it is remarkable that predomi-
nantly upregulated genes indicate severe disease, whereas only decreased cell populations are
observed [14]. To validate the OLFM4 gene expression changes during infectious disease we
data-mined other micro-array studies that described pediatric and adult patient cohorts. In a
study by Ioannidis et al. (GSE 34205), we found that OLFM4 gene expression was higher in
PBMCs obtained from patients with RSV (n = 51) or influenza virus (n = 27) infections com-
pared to the gene expression in healthy infants (n = 22), p<0.01 and p<0.0001, respectively
[31]. No differences were found in OLFM4 gene expression between children under or above
three months of age with either infection by RSV or influenza. In contrast, two other studies
did not observe upregulation of OLFM4 in PBMCs from children during infection by measles
or rotavirus (GSE 5808 and 2729) [32, 33]. Zaas et al. performed microarrays on whole blood
obtained from adult volunteers at baseline and at the peak of their symptoms after being exper-
imentally infected with RSV, influenza or rhinovirus (GSE 17156) [34]. Although their data
showed an upregulation of OLFM4 in RSV infected adults (p = 0.01), there were no differences
in OLFM4 gene expression between the baseline and during symptomatic influenza or rhinovi-
rus infections [34]. Data of Ramilo et al. (GSE 6269–1) showed a statistically significant upre-
gulation of OLFM4 in children, aged 0–16 years, diagnosed with influenza virus or bacterial
infections (E. coli, S. aureus or S. pneumoniae) compared to healthy controls [20]. In this
cohort, children with S. aureus or S. pneumoniae infections had statistically significantly higher
OLFM4 gene expression compared to influenza A infected patients [20]. Thus, other studies
have also seen upregulation of OLFM4 expresion after bacterial or viral infection. However,
none of the studies looked at disease severity.
OLFM4, also known as hGC-1 and GW112, was first cloned from G-CSF–stimulated
human myeloid precursor cells and is mainly expressed in bone marrow, gastro-intestinal
tract, prostate and pancreas [35]. Earlier studies have shown that OLFM4 is involved in multi-
ple cellular functions e.g. cell growth, differentiation and apoptosis [27]. OLFM4 expression
has been reported as one of several (prognostic) markers in oncology [27]. In addition, its
involvement in the immune response to inflammation has been described. OLFM4 expression
is upregulated in some inflammatory diseases, such as chronic inflammatory bowel diseases
[36] and inHelicobacter pylori-infected patients [37]. Liu et al. showed an enhanced immune
response and inflammation in OLFM4-/- mice upon Helicobacter pylori infection. Their results
indicate that OLFM4 inhibits NOD1 and NOD2-mediated NF-κB activation, suggesting that
OLFM4 plays an important role in regulating innate immune responses [38]. In another study,
Liu et al. demonstrated that neutrophils from OLFM4 -/- mice have increased capability to
kill S. aureus and E. coli and are more resistant to systemic sepsis [39]. These data suggest that
Table 4. Relative risk of gettingmechanical ventilation determent by OFFM4 gene expression. OR = odds ratio, CI = confidence interval
Multivariate analysis p-value OR 95% (CI) Relative risk
OLFM4 expression> -7.5 <0.01 15.78 1.93–46.57 8.7
doi:10.1371/journal.pone.0131927.t004
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OLFM4 may be an important regulator of host innate immunity against a broad array of bacte-
rial infections. Data mining of gene expression profiling datasets (www.immgen.org) indicates
that OLFM4 is besides being expressed in neutrophils, also highly expressed in Th1 cells.
Therefore the increased OLFM4 expression seen in the severe subgroup may indicate an highly
active ongoing Th1 response. In summary, OLFM4 was upregulated in several viral and bacte-
rial infections in many (but not all) previously published studies investigated.
Although OLFM4 mRNA has been described to be selectively expressed in normal human
myeloid lineage cells, OLFM4 protein concentrations have been measured in PBMCs, B-lym-
phocytes, neutrophils and monocytes [40]. This is in agreement with our results and those
from the reanalyzed microarray studies, in which high and significantly different OLFM4
mRNA expression was found in PBMCs obtained from children with different severity of viral
lower respiratory infections.
Clemmensen et al. showed that OLFM4 was present at protein level in only 20–25% of
peripheral blood neutrophils, whereas mRNA for OLFM4 was present in all myelocytes and
metamyelocytes, indicating post-transcriptional regulation as a basis for the heterogeneous
expression of OLFM4 protein [41]. This could explain the observed differences in our study
between the transcription levels and the plasma concentration of the protein.
The advantage of measuring markers in plasma is the ease of implementation, speed, repro-
ducibility and standardization. However, innovative techniques enable rapid analysis of the
expression of multiple genes at transcriptional level in the near future [42].
The severe CD4, CD8 and NK cell lymphopenia that we and others described before, can
now be better explained. Together with the up regulation of activation markers on PBMC in
the severe group and lack of apoptosis, the observed lymphopenia likely results from recruit-
ment of T cells to the site of infection, i.e the lungs with an parent lower cell count in peripheral
blood. In this respect peripheral blood may not reflect the situation in all parts of the body.
OLFM4 is associated with Th1 responses, an active or even overaggressive Th1 response may
underlie the severe clinical manifestations in this group. This is reminiscent of interpretations
in the early RSV vaccine trails. Nevertheless, more accurate measurements at the site of infec-
tion will be needed to determine whether in the severe cases an inadequate adaptive immune
response or a hyper responsive reaction (for instance by excessive production of cytokines) is
responsible for the severe manifestations of RSV infection.
Notwithstanding this uncertainty, in this study we are the first to show that OLFM4 tran-
scription is associated with severity of disease in children with viral lower respiratory tract
infections, also after correcting for age. These results emphasize the role of OLFM4 in innate
and adaptive immunity and encourages further research into the presence of OLFM4 in
PBMCs and the pathogenesis of RSV infections. Moreover, it could lead to the development of
a new diagnostic tool to predict a severe course of viral respiratory disease and aid the physi-
cian in clinical decisions.
Supporting Information
S1 Fig. Transient lymphopenia during severe RSV infection. Immune phenotyping with
flowcytometry of circulating leukocytes of infants with severe RSV infection (n = 6) in the
acute phase and after clearance of the infection (on average 4 weeks after discharge). The num-
bers of NK cells as well as CD4+ and CD8+ T cells return to normal, indicating that the lym-
phopenia was transient. Statistics were performed by paired students-t test, significance was set
at p<0.05.
(TIF)
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S2 Fig. Discriminating mild disease from severe disease in children with RSV infection. 448
differentially expressed probesets were selected based on overlap in the comparison mild vs
severe disease in RSV infected children and acute samples vs recovery samples of children with
severe RSV infection. Samples were clustered based on these selected probesets by complete
linkage hierarchical clustering with 1-correlation as a distance measure.
(TIF)
S3 Fig. OLFM4 gene expression values in PBMCs from RSV+ infants during acute mild,
moderate and severe viral lower RTI and after recovery. Expression levels are presented as
ΔCt and median with inter quartile range (IQR). Statistics were performed by Kruskall Wallis
tests (p<0.001), followed by MannWhitney U tests for individual comparisons: mild vs mod-
erate p = 0.36, moderate vs severe p<0.001, mild vs severe p = 0.51.
(TIF)
S1 Table. Patient characteristics of validation cohort. Values are given in numbers (percent-
ages) and median and inter quartile range (IQR  mild versus severe p = 0.05, moderate versus
severe p<0.001  mild versus moderate and severe p<0.001, moderate versus severe p<0.001
 mild versus moderate p<0.01, mild versus severe p<0.05.
(DOCX)
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